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Embryonic stem cells (ESCs) are an emerging source for cell-based therapies aimed at repairing damaged
organ tissues; however, the efficiency of directed differentiation is low and refinement of differentiation
protocols is hampered by incomplete understanding of the mechanisms involved in this process. To find
new compounds which can improve the efficiency of directed differentiation of ESCs to cardiomyocytes,
we screened several thousand chemical compounds and identified a promising group. All of the
compounds found have a common structure of 1H-pyrrole,2,2'-(phenylmethylene)bis. Here we report the
potential mechanism of action for 31002 which showed the strongest activity among the compounds
selected. In the presence of 31002, 15 times more cardiomyocytes differentiated from ESCs, i.e., 3.5% to
52% of total differentiated cells. Moreover, the cardiomyocytes showed functional characteristics including
rhythmic beating and marker gene expression. 31002 inhibited the down-regulation of genes related to
the three germ layers in the late stage of ESCs differentiation, implying that 31002 supports a continuous
fate commitment of undifferentiated ESCs to the cardiac lineage by prolonging the three germ layer
stages. Therefore, compounds in this group, including 31002, might be useful as directed cardiomyogenic
differentiation-inducers to produce cells for use in cell therapy aimed at restoring damaged heart tissue.
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Chronic heart failure is currently incurable and a leading
cause of death worldwide [1,2]. Myocardial infarction
contributes to chronic heart failure by inducing myocardial
cell death [3]. At present the only effective treatment for
patients with chronic heart failure is donor or artificial heart
transplantation [4]. Therefore, finding new therapeutic
approaches is critical. Recent progress in stem cell science
is providing potential therapeutic options for heart disease
patients [2,5].
Most tissues have endogenous stem/progenitor cells, which
upon injury to the organ, can proliferate and differentiate
at the injury site to repair damaged tissue [6-9]. Although
the adult heart is composed of postmitotic and terminally
differentiated cells, there is also a small subpopulation of
myocardial cells with cardiac stem cell characteristics [10,11];
however, their limited availability prevents them from being
used in therapeutic applications.
In contrast, embryonic stem cells (ESCs) are available in
considerable numbers and have become strong candidates
as a cell source for cardiac repair [12,13]. ESCs are
unspecialized precursor cells with the capability to self-renew
and differentiate into specialized cells in response to
appropriate signals [14].There are several small molecules
known to have enhancing effects for cardiomyogenic
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differentiation of ESCs including retinoic acid [15], ascorbic
acid [16], dimethyl sulfoxide (DMSO) [17], and oxytocin [17].
Although these compounds can support directed differentiation
of ESCs to cardiomyocytes, the efficiency is insufficient for
therapeutic applications. Therefore, new molecules with
improved efficiency would have a great impact on the
preparation of cardiomyocytes for clinical applications. To
identify those molecules, we used a cell-based screening system
with ESCs stably transfected with a vector carrying a cardiac
specific α-myosin heavy chain (MHC) gene promoter-driven
enhanced green fluorescent protein (EGFP) [18]. We
successfully identified a group of compounds which acted
as directed cardiomyogenic stimulants. Here we report the
activity and possible mechanism of action of one such
compound.
Materials and Methods
ESC line
The 129 strain-derived KH2 ESCs which were stably
transfected with an α-MHC promoter-driven EGFP expression
vector, were previously described [18]. The cells were grown
on irradiated mouse embryonic fibroblast feeder layers in
high glucose Dulbecco’s modified Eagle medium (DMEM;
Gibco/BRL, Grand Island, NY, USA) supplemented with 15%
ES-qualified fetal bovine serum (FBS; Hyclone, South Logan,
UT, USA), 2 mM L-glutamine (Gibco/BRL), and 10 µM  β-
mercaptoethanol (Sigma-Aldrich, St. Louis, MO, USA) at 37
oC
in 5% CO2.The ESCs were subcultured every two days.
Cardiomyogenic differentiation protocol for ESCs
Undifferentiated KH2 cells were trypsinized and suspended
at a concentration of 3.2×10
4 cells/mL in differentiation
medium [ESC culture medium with 20% FBS and 0.1 mM
non-essential amino acids (Gibco/BRL)] on differentiation day
(DD) 0. To form embryoid bodies (EBs), 25 µL-drops of cell
suspension (800 cells/drop) were incubated in a 5% CO2
incubator as hanging drops for three days. EBs were collected
on DD3 and three EBs were placed in each well of a 96-
well plate and cultured for 12 days with differentiation
medium. The differentiation medium was changed every 1-
2 days during the culture period. Differentiated cells on DD15
were trypsinized, fixed with 1% formalin in phosphate-buffered
saline (PBS), and subjected to flow cytometric analysis
(FACScalibur; Becton-Dickinson, San Jose, CA, USA) for
detection of EGFP-expressing cells.
Screening of test compounds
Test compounds prepared in DMSO were obtained from
the Korea Chemical Bank (Daejeon, Korea). The compounds
were diluted with differentiation medium [1/160-1/1,000 final
dilutions (equal to 1.6-5 µM of final concentration) depending
on the provided concentrations]. For the first and second
round of screening, test compounds were added to each
well of a 96-well plate including three EBs of KH2 cells from
DD3 to DD15. The differentiation medium including the
test compound was changed every 1 or 2 days. Differentiated
cells on DD15 were subjected to fluorescence activated cell
sorter (FACS) analysis as described previously.
Reverse transcriptase-polymerase chain reaction
(RT-PCR) analysis
Total RNA from cells at different differentiating stages was
extracted using RNeasy Kits (Qiagen, Hilden, Germany), and
cDNA was synthesized from the total RNA with SuperScript
II reverse transcriptase (Invitrogen, Carlsbad, CA, USA)
according to the manufacturers’ instructions. PCR amplification
of the murine genes was carried out as described in Table
1. Gene expression levels were normalized to the β-actin
level. At least three independent experiments were performed.
Immunocytochemical staining
To confirm that the EGFP-expressing cells were
cardiomyocytes, marker protein expression for cardiomyocytes
was demonstrated by immunocytochemistry. In brief, EBs on
DD3 were transferred on a coverslip coated with 0.1% gelatin
and cultured with medium including 10 mM 31002 until
DD15. Differentiated cells on DD15 were fixed in neutral
10% formalin for 10 min, washed three times with PBS, and
blocked with PBS containing 0.3% bovine serum albumin
(BSA) and 1% goat serum at room temperature for 40 min.
The cells were incubated with anti-α-actinin (EA-53, Sigma,
St. Louis, MO, USA) or anti-troponin T (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) monoclonal antibodies
at a dilution of 1:800 or 1:200, respectively, at room
temperature for 1 h. After washing with PBS, rhodamine-
labeled goat anti-mouse IgG (KPL, Gaithersburg, MD, USA)
was applied at room temperature for 1 h. After a brief
incubation with 4’,6-diamidino-2-phenylindole (DAPI; KPL)
for nuclear staining, the cells were observed with a fluorescence
microscope (BX62, Olympus, Tokyo, Japan).
Data analysis
Data were analyzed by non-parametric one-way analysis-
of-variance using the Kruskal Wallis test, followed by Dunnett’s
test for multiple comparisons to vehicle control. All statistical
analyses were performed with SPSS for Windows (SPSS Inc.,
Chicago, IL, USA).Cardiomyogenic stimulant 31002 207
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Results
Screening  for  chemical  compounds  causing  an
increase of EGFP-expressing cells
We obtained 6,480 structurally representative compounds
from the Korea Chemical Bank. The compounds were
screened for their ability to enhance the appearance of EGFP-
expressing cells from KH2 ESCs after differentiation for 15
days as described in Methods. The screening identified one
active compound. Subsequently, 50 structural derivatives of
the active compound containing a common chemical structure
of 1H-pyrrole,2,2'-(phenylmethylene)bis were also subjected
to screening. Of those, 12 showed outstanding activity (Figures
1 and 2). Two compounds, 30984 and 31002, had the highest
activity and showed dose-dependent activity. Based on
availability, we selected 31002 for further characterization.
31002 increases EGFP-positive cells with characteristics
of functional cardiomyocytes
The EGFP-expressing cells derived from KH2 ESCs in the
presence of 31002 were easily detected by flow cytometry
(Figure 3A).
To confirm that the EGFP-expressing KH2 cells had
characteristics of cardiac cells, we performed immuno-
fluorescence staining for the cardiac marker proteins α-actinin
and troponin T (Figure 3B). EBs cultured on coverslips with
or without 31002 were stained for the markers as described
in Methods. As expected, almost all EGFP-expressing cells
co-expressed troponin T and α-actinin, irrespective of the
presence of 31002. Notably, EGFP-positive cell clumps
differentiated with 31002 were much larger than those of
the vehicle control. Furthermore, EGFP-expressing cell clumps
could be identified within all the spontaneous beating areas
in EBs when observed with a fluorescence microscope prior
to fixation (data not shown). These results suggest that EGFP-
expressing cells derived from KH2 ESCs in the presence of
31002 are functional cardiomyocytes.
31002 acts in the late stage of ESC differentiation
When KH2 ESCs were differentiated with 31002, the EGFP-
expressing cell clumps were hardly observed until DD8, after
which, an abrupt increase in the cell ratio was observed
between DD8 and DD12 (Figure 4). The increase reached
a peak of 52% at DD17 and remained at that level with
a small fluctuation until DD34. In contrast, the ratio in vehicle
controls remained under 4% during the entire experimental
period.
To determine the critical time point of 31002 action in
cardiomyogenic differentiation of ESCs, seven experimental
cell groups were treated with 31002 at different time points
Table 1. PCR conditions for gene expression analysis
Gene names Forward and reverse primers  PCR conditions* Expected size (bp)
Nkx2.5 5'-cgacggaagccacgcgtg-3' 
5'-ccgctgtcgcttgcact-3'  94-60-72, 30cy 181
GATA4 5'-cgagatgggacgggacact-3' 
5'-tgagtgacaggagatgcatag-3'  94-58-72, 30cy 620
α-MHC 5'-ctgctggagaggttattcc-3' 
5'-ggaagagtgagcggcgcatcaa-3'  94-64-72, 30cy 301
MLC-2v 5'-gaaggctgactatgtccgggagat-3' 
5'-tgtgggtcacctgaggctgtggttc-3'  94-60-72, 30cy 189
α-fetoprotein 5'-cctatgcccctcccccattc-3' 
5'-ctcacaccaaagcgtcaacacatt-3'  94-55-72, 30cy 334
Foxa2 5'-actggagcagctactacg-3' 
5'-cccacataggatgacatg-3'  94-55-72,35cy 152
Brachyury 5'-atgccaaagaaagaaacgac-3' 
5'-agaggctgtagaacatgatt-3'  94-55-72, 30cy 815
Flk1 5'-cacctggcactctccaccttc-3' 
5'-gatttcatcccactacccaaag-3'  94-55-72, 30cy 239
Pax6 5'-tcacagcggagtgaatcag-3' 
5'-cccaagcaaagatggaag-3'  94-58-72,30cy 332
FGF5 5'-aaagtcaatggctcccacgaa-3' 
5'-cttcagtctgtacttcactgg-3'  94-58-72, 30cy 444
Oct4 5'-ggcgttctctttggaaaggtgttc-3' 
5'-ctcgaaccacatccttctct-3'  94-55-72, 30cy 302
*PCR temperatures for denaturation, annealing, and elongation and the number of cycles, respectively.208 Eun Kyoung Kim et al.
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for three days. Cells in all groups were analyzed for EGFP
positivity by flow cytometry on DD15 (Figure 5). Interestingly,
group 7 which was treated with 31002 only for the last 3
days, showed a comparable EGFP-positive cell ratio to those
in groups 1 and 2 in which 31002 was applied for 12 and
15 days, respectively. An intermediate EGFP-positive cell ratio
was observed in group 6 which was treated with 31002
for three days between DD9 and DD12. However, there
was no detectable 31002 effect in any groups in which a
three-day treatment was applied between DD0 and DD9.
31002 affects on germ layer marker gene expressions
To obtain information related to the mechanism of action
of 31002 in ESC differentiation, time-dependent expression
patterns of developmental marker genes were analyzed in
the cells at different stage of differentiation. KH2 cells were
differentiated for 15 days as described in Materials and
Methods in the presence of 10 µM 31002 or vehicle (0.1%
DMSO). The expression of marker genes for endodermal
(AFP and Foxa2), mesodermal (Brachyury and Flk1), and
ectodermal (FGF5 and Pax6) [19,20] levels were analyzed
(Figure 6A).
The Foxa2 expression level in 31002-treated cells was much
lower than that in the vehicle control on DD3. However,
the level showed a gradual increase with time in 31002-
treated cells and a gradual decrease in vehicle control cells
and was reversed between the cell groups by DD15. In the
case of FGF5 expression, high expression levels observed on
DD3 decreased abruptly in both cell groups by DD 9. However,
full-recovery of the FGF5 expression level was observed by
DD15 in 31002-treated cells, but not in vehicle control cells
(Figure 6A). It should also be noted that there was a tendency
for higher expression of Flk1 and Pax6 genes in 31002-treated
cells compared to vehicle control cells in the late differentiation
stage (between DD12 and DD15).
31002 affects on cardiac marker gene expressions
Nkx2.5 and GATA4 are required for cardiac commitment
of mesodermal cells and are known to be expressed in the
early stage of cardiac differentiation [19,20]. On the contrary,
α-MHC and MLC-2v are cellular components of
cardiomyocytes; therefore, these molecules are known to
appear at the later stage of differentiation. In the present
study, 31002 treatment inhibited the abrupt down-regulation
Figure 1. Chemical structure of 31002 and the structural derivatives showing activity propensity for cardiomyocyte-directed
differentiation of embryonic stem cells (ESCs).
Figure 2. Activity of test compounds for cardiomyogenic
differentiation induction of ESCs. KH2 ESCs were differentiated
with one of the compounds at a final concentration of 1or 10
mM as described in Materials and Methods. On day 15 of
differentiation, the cells were trypsinized, fixed with 1%
formaldehyde and subjected to fluorescence activated cell
sorter (FACS) analysis to detect enhanced green fluorescent
protein (EGFP) expressing cells. Three independent experiments
were repeated and the representative result is shown. All the
experiments were done in triplicate.Cardiomyogenic stimulant 31002 209
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of  Nkx2.5  gene expression shown in vehicle control cells
at the late stage of differentiation (Figure 6B). However, no
effect of 31002 treatment was observed on the expression
ofGATA4.  For  α-MHC and MLC-2v, as expected from the
higher EGFP expressing cell ratio, a much higher expression
level was observed in 31002-treated cells compared to that
of vehicle controls on DD15.
Discussion
ESCs are one of the most promising tools for cell-based
therapy to recover damaged myocardium [2]. However, in
order for ESCs to be applicable for clinical use, many limitations
must be resolved. One critical limitation is the inefficiency
Figure 3. Co-expression of cardiomyocyte marker proteins in EGFP-expressing cells. (A) Representative flow cytometric plots of
differentiated KH2 cells in the presence of 10 mM 31002. KH2 ESCs were differentiated with 10 mM 31002 as described in
Materials and Methods. On day 15 of differentiation, the cells were trypsinized, fixed with 1% formaldehyde and subjected to FACS
analysis to detect EGFP expressing cells. (B) Differentiated cells on day 15 were fixed and immunostained for troponin T (b and d;
red) or α-actinin (f; red) as described in Materials and Methods. EGFP (green) in the cells was observed under a fluorescence
microscope (a, c and e). Three independent experiments were repeated and the representative results are shown. Troponin T
(×100), α-actinin (×200). 
Figure 4. Time-dependent increase of EGFP-positive cells.
KH2 ESCs were differentiated with 10 mM 31002 as described
in Materials and Methods. On the differentiation days indicated,
the cells were trypsinized, fixed with 1% formaldehyde, and
subjected to FACS analysis to detect EGFP expressing cells.
Three independent experiments were repeated and the
representative results are shown. All experiments were
performed in triplicate.
Figure 5. The effects of periodic 31002 treatments on
cardiomyogenic differentiation of ESCs. KH2 cells were
differentiated for 15 days according to the differentiation
protocol described in Materials and Methods. The cells were
treated with 10 µM 31002 during only the indicated period. On
day 15, flow cytometric analysis was performed for all cell
groups. Three independent experiments were repeated and
representative results are shown. All experiments were
performed in triplicate. *Significant difference at P<0.05
compared to Group 1.210 Eun Kyoung Kim et al.
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of directed differentiation of ESCs to cardiomyocytes. To
overcome this hurdle, various genetic techniques, protein
factors, and chemical compounds [19-21] have been applied
to optimize differentiation protocols. Known biologically active
molecules used for this purpose include periostin [11],
transforming growth factor beta (TGFwith bone morphogenetic
protein 2 (BMP2) [20,22,23], insulin-like growth factor (IGF)
[19], nitric oxide [24], reactive oxygen species [25], and
oxytocin [17]. Several chemical compounds such as 6-
bromoindirubin-3'-oxime (BIO) [21], ascorbic acid [16,26],
retinoic acid, and DMSO [17] are known to induce
cardiomyocyte differentiation of ESCs as well. Although
significant progress has been made in producing cardiac lineage
cells, the efficiency for directed differentiation of ESCs to
cardiomyocytes is currently insufficient for clinical utility and
our limited understanding of the mechanisms involved in
the process further limits the refinement of differentiation
protocols.
To break through these current limitations, we attempted
to identify new compounds with the potential to induce
directed differentiation of ESCs to cardiomyocytes. For this
purpose, we established a screening system using KH2 ESCs
stably transfected with an α-MHC promoter-driven EGFP
expression vector [18]. The cells were successfully used to
identify a group of compounds, including 31002, which could
act as cardiomyocyte-directed differentiation stimulants for
ESCs. Those found to be active had a common structure
of 1H-pyrrole,2,2'-(phenylmethylene)bis and their effect was
dose-dependent. We also observed an indication that 31002
might have cardiomyogenic differentiation-enhancing activity
in human ESCs (our unpublished data). Clarification as to
the action mechanism of 31002 with regard to cardiomyogenic
differentiation of ESCs will be beneficial to this area of research. 
In contrast to several other cardiomyogenic stimulants for
ESCs which are known to elicit their effects during the early
stages of differentiation [15,16], the stimulating effect of 31002
was obvious only with treatment during the later stages of
ESC differentiation. When KH2 cells were differentiated
according to the protocol described in Methods without
31002, the once elevated expressions of Nkx2.5, α-MHC,
and MLC-2v in the middle stages of differentiation declined
in the later stages. This change can be attributed to the relative
decrease in the ratio of cardiomyocytes among the total cells.
However, KH2 cells differentiated in the presence of 31002
did not down-regulate gene expression, and even showed
enhanced expression in the case of Nkx2.5 and MLC-2v in
Figure 6. Marker gene expressions of differentiating ESCs. KH2 ESCs were differentiated in the presence of 10 µM 31002 as
described in Materials and Methods. Total RNA was obtained from the differentiating cells collected at the indicated times. Marker
genes for three germ layers (A) and cardiac lineage cells (B) were analyzed by semi-quantitative RT-PCR. The plots in the right
panel show the relative expression levels of target genes which were normalized to β-actin expression. Open- and filled-symbols
indicate dimethyl sulfoxide (DMSO) and 31002 treatments, respectively.Cardiomyogenic stimulant 31002 211
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the later stage of differentiation. This finding is consistent with
the abrupt increase in the ratio of cardiomyocytes in cells
differentiated with 31002.
Embryonic developmental studies showed that endodermal
factors such as Nodal, BMP2, FGFs, and Shh affect cardiac
development [20,27]. In the present study, although the
expression of the endodermal marker Foxa2 was inhibited
in the early differentiation stage by 31002 treatment, it was
gradually promoted with time, resulting in much higher
expression in the later stage of differentiation compare to
vehicle control cells. Activation of endodermal cells might
be connected to the increased production of endodermal
factors which can stimulate cardiomyogenic differentiation.
The ectodermal marker gene FGF5 also showed an unusual
increase in the later stage of differentiation with 31002
treatment. It should also be noted that the Pax6 expression
levels in 31002-treated cells was superior to that in vehicle
control cells during the later stages of differentiation.
Collectively, these results imply that 31002 may inhibit early
activation of the three germ layer-forming stages and prolong
the stage which is indispensable for cardiomyogenic
commitment of ESCs. These results are consistent with the
observation that the EGFP expressing cell ratios in 31002-
treated cells during the last three differentiation days were
similar to those in cells treated with 31002 for all the
differentiation periods.
Again, this finding could also explain why the expression
levels of Nkx2.5, α-MHC, and MLC-2v are maintained high
or even increased in the later stage of the differentiation
period. The Nkx2.5 gene is expressed during the cardiac
commitment of mesodermal cells and is known to be expressed
in the early stage of cardiac differentiation [19]. Therefore,
provided that the three germ layer stages continue until DD15,
cardiac committed cells expressing Nkx2.5 will be increased,
resulting in remarkable increases of cardiomyocytes and
increased expression of α-MHC and MLC-2v genes. The effect
of 31002 in ESC differentiation appears to be specific to
the cardiomyogenic pathway, because we could not detect
any enhancing effects on hematopoietic lineage or neuronal
lineage cell differentiations (our unpublished data).
In conclusion, 31002 might support a continuous fate
commitment of undifferentiated ESCs to the cardiac lineage
by prolonging the early differentiating stage, resulting in an
increase of cardiomyocytes. Therefore, the compounds in
this group, particularly 31002, might be used as a directed
cardiomyogenic differentiation inducer to produce cells for
cell therapy to repair damaged heart tissue.
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